Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer

• Published in: Cancer chemotherapy and pharmacology 1985-01, Vol.15 (1), p.86-87
• Main Authors: WAGENER, D. J. T, YAP, S. H, WOBBES, T, BURGHOUTS, J. T. M, VAN DAM, F. E, HILLEN, H. F. P, HOOGENDOORN, G. J, SCHEERDER, H, VAN DER VEGT, S. G. L
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Bone Marrow - drug effects; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Drug Evaluation; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Humans; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Stomach Neoplasms - drug therapy
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/BF00257302

Twenty patients (15 male, 5 female) with nonresectable gastric adenocarcinoma were treated with FAP (5-fluorouracil 300 mg/m2 IV on days 1-5, adriamycin 50 mg/m2 IV on day 1, cisplatin 20 mg/m2 IV on days 1-5). Each course was repeated every 21 days. Eighteen patients were evaluable for response. The median age was 51 years, the range extending from 34 to 68. None had undergone chemotherapy. The median Karnofsky performance score was 80%. Nine (50%) partial responses (PR) and eight (44%) cases of stable disease (SD) were observed. One patient showed progression of the disease and died after 6 months. The median duration of response was 6+ months for PR and 6 months for SD. The median survival was 12 months. FAP toxicity was moderate, with the median WBC nadir 3.2 X 10(9)/l (range 0.7-4.2). One patient in PR died of septicemia. Nausea and vomiting were not dose-limiting. Neuropathy was mild in four and moderate in two patients. This FAP combination appears to be as effective with respect to response rate and duration as reported for 5-fluorouracil, adriamycin and mitomycin C (FAM).